2600 - assessment of quality of life in patients with metastatic melanoma in real clinical practice in france

Background

Significant advances were recently observed in the treatment of metastatic melanoma (MM). With 60% of patients now reaching a second line of treatment (trt) and a significant improvement in survival, the assessment of quality of life (QoL) during whole disease is necessary. The objective of this work is to describe the evolution of QoL of patients (pts) over trt lines until death.

Methods

QoL is collected through MelBase, a prospective French multicentric cohort dedicated to the follow-up of adults with MM. It is assessed using the EQ-5D (called utility, with range 0-1) and the FACT-M (score range 0-172) questionnaires, at inclusion (i.e. at MM diagnosis) and then every 3 months or at each trt change, until death. Evolution of QoL as compared to the beginning of the 1^st line is described at the beginning of the 2^nd line, at progression and one month before death.

Results

QoL is assessed on 1183 pts included between 2013 and 2017. Median follow-up is 12 months and 605 patients died during follow-up. At inclusion, the mean score is 0.831 [CI_95%: 0.817; 0.843] for utility and 128.487 [CI_95%: 127.047; 129.924] for FACT-M scores. Between baseline and 6 months of 1^st trt line, QoL decreased of 0.008 [CI_95%: -0.010; 0.030] (-0.8%) for utility score and of 1.62 [CI_95%: -0.770; 4.010] (-0.9%) for the FACT-M scores compared to baseline, whereas it evolves of -0.003 [CI_95%: -0.030; 0.010] (-0.3%) for utility score and of 0.256 [CI_95%: -2.550; 3.060] (0.2%) for the FACT-M at the beginning of 2^nd line. At progression, QoL evolves of -0.015 [CI_95%: -0.03; 0.01] (-1.5%) for utility score and of -2.640 [CI_95%: -1.420; 3.450] (1.5%) for the FACT-M. The greatest QoL deterioration was observed one month before death by -0.129 [CI_95%: -0.170; -0.090] (-13%) for utility score and by 18.961 [CI_95%: -22.880; -15.040] (11%) for the FACT-M score.

Conclusions

In Melbase cohort, patient’s QoL with MM seems to be fairly stable through trt lines and disease progression. The QoL of pts appears to be mainly degraded during the "pre-death" period. Complementary analyses are ongoing to evaluate the impact on prognostic factors, treatments and time on the evolution of QoL.

Clinical trial identification

Legal entity responsible for the study

DRCI AP-HP.

Funding

National Cancer Institute (INCa).

Editorial Acknowledgement

Disclosure

C. Allayous: Travel, accomodations, expenses: BMS, Amgen. S. Dalle: Research funding (institution): Roche, BMS; Travel, accomodations, expenses: BMS, MSD. L. Mortier: Travel, accomodations, expenses: BMS, Novartis, Roche. S. Dalac Rat: Honoraria: BMS; Consulting or advisory role: Roche, BMS; Speakers' bureau: BMS; Travel, accomodations, expenses: BMS, Roche. C. Dutriaux: Consulting or advisory role: Roche, BMS, Novartis, MSD. P. Saiag: Honoraria: BMS, Roche, MSD, Novartis, Array, Pierre-Fabre; Consulting or advisory role: BMS, Roche, MSD, Novartis, Array, Pierre-Fabre; Research funding: Roche; Travel, accomodations, expenses: BMS, Roche, MSD, Novartis. J.-P. Lacour: Honoraria: BMS; Research funding (institution): Roche, BMS,Novartis, GSK. D. Legoupil: Honoraria: BMS Consulting or advisory role: BMS; Travel, accomodations, expenses: BMS. A. Bardet: Employee, Shareholder: Roche. C. Lebbe: Honoraria: BMS, Roche, MSD, Novartis, Amgen; Consulting or advisory role: BMS, Roche, MSD, Novartis, Amgen; Speakers' bureau: Roche, MSD, Novartis, Amgen; Research funding: Roche, BMS; Travel, accomodations, expenses: BMS, Roche, Amgen. I. Borget: Honoraria: BMS, Roche, Janssen Consulting or advisory role: BMS, Roche, Novartis, Janssen, Merck; Travel, accomodations, expenses: Janssen, Merck, Novartis, Roche. All other authors have declared no conflicts of interest.